» Articles » PMID: 25261721

Breast Cancer Stem Cells, EMT and Therapeutic Targets

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2014 Sep 28
PMID 25261721
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

A small heterogeneous population of breast cancer cells acts as seeds to induce new tumor growth. These seeds or breast cancer stem cells (BCSCs) exhibit great phenotypical plasticity which allows them to undergo "epithelial to mesenchymal transition" (EMT) at the site of primary tumor and a future reverse transition. Apart from metastasis they are also responsible for maintaining the tumor and conferring it with drug and radiation resistance and a tendency for post-treatment relapse. Many of the signaling pathways involved in induction of EMT are involved in CSC generation and regulation. Here we are briefly reviewing the mechanism of TGF-β, Wnt, Notch, TNF-α, NF-κB, RTK signalling pathways which are involved in EMT as well as BCSCs maintenance. Therapeutic targeting or inhibition of the key/accessory players of these pathways could control growth of BCSCs and hence malignant cancer. Additionally several miRNAs are dysregulated in cancer stem cells indicating their roles as oncogenes or tumor suppressors. This review also lists the miRNA interactions identified in BCSCs and discusses on some newly identified targets in the BCSC regulatory pathways like SHIP2, nicastrin, Pin 1, IGF-1R, pro-inflammatory cytokines and syndecan which can be targeted for therapeutic achievements.

Citing Articles

siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.

Chaudhary P, Yadav K, Lee H, Kang K, Mo J, Kim J Breast Cancer Res. 2024; 26(1):72.

PMID: 38664825 PMC: 11046805. DOI: 10.1186/s13058-024-01827-4.


Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.

Bonni S, Brindley D, Chamberlain M, Daneshvar-Baghbadorani N, Freywald A, Hemmings D Cancers (Basel). 2024; 16(5).

PMID: 38473273 PMC: 10931297. DOI: 10.3390/cancers16050911.


C1ql4 regulates breast cancer cell stemness and epithelial-mesenchymal transition through PI3K/AKT/NF-κB signaling pathway.

Xu F, Wang J, Zhen S, Duan Y, Li Q, Liu L Front Oncol. 2023; 13:1192482.

PMID: 37324011 PMC: 10265994. DOI: 10.3389/fonc.2023.1192482.


Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells.

Mazurakova A, Koklesova L, Vybohova D, Samec M, Kudela E, Biringer K Front Pharmacol. 2023; 14:1160068.

PMID: 37089930 PMC: 10115970. DOI: 10.3389/fphar.2023.1160068.


Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy.

Balahura Stamat L, Dinescu S, Costache M Int J Mol Sci. 2023; 24(4).

PMID: 36834660 PMC: 9963301. DOI: 10.3390/ijms24043245.